EEG device 510(k)s need clinical data for most diagnostic claims -- FDA draft guidance.
This article was originally published in The Gray Sheet
Executive Summary
EEG DEVICE 510(k)s NEED CLINICAL DATA FOR DIAGNOSTIC CLAIMS OTHER THAN EPILEPSY, FDA says in a draft guidance on 510(k)s for electroencephalograph devices. Noting that the only diagnostic EEG claim that has been cleared via 510(k) is "aiding the physician in diagnosing epilepsy," FDA says that "any other intended use, including diagnostic claims that the manufacturer makes about the device's capabilities, should be supported by clinical data." Comments on the guidance are due by Jan. 2.
You may also be interested in...
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.